A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
Status:
Recruiting
Trial end date:
2027-06-09
Target enrollment:
Participant gender:
Summary
The researchers are doing this study to find out whether the study vaccines, IO102/IO103,
given in combination with the standard-of-care drug combination, nivolumab and relatlimab, is
a safe and effective treatment for people with untreated, unresectable melanoma.